The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy.

The mind-boggling progress in the understanding of the molecular mechanisms underlying the long QT syndrome (LQTS) has been the subject of many articles and reviews. Still, when it comes to the management of the patients affected by this life-threatening disorder, too many errors still take place, both in the diagnostic process and in the therapeutic choices. The price of these errors is paid by the patients and their families. This review is not directed to the relatively small number of LQTS experts who know what to do. It does not deal with genetics, with epidemiology, or with the well-known clinical manifestations. We have focused solely on the approach to diagnosis and therapy and we have directed this review to the average clinical cardiologist who, in his/her practice, sees occasionally patients affected or suspected to be affected by LQTS; the cardiologist who may know enough to manage them but not enough to be completely confident on his/her most critical choices. We have provided our personal views without making any attempt to blend differences whenever present. On most issues we agree fully but where we do not, we make it clear to the reader by indicating who is thinking what. The result may be unconventional, but it mirrors the challenges, often severe, that we all face in managing and protecting these patients from sudden death while also helping them live and thrive despite their diagnosis. We trust that this unabashed presentation of our clinical approach will be useful for both cardiologists and patients.

[1]  P. Schraeder,et al.  Stress and sudden death , 2006, Epilepsy & Behavior.

[2]  S. Priori,et al.  Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. , 1995, Circulation.

[3]  M. Ackerman,et al.  The diagnostic utility of recovery phase QTc during treadmill exercise stress testing in the evaluation of long QT syndrome. , 2011, Heart rhythm.

[4]  P. Schwartz.  Efficacy of left cardiac sympathetic denervation has an unforeseen side effect: medicolegal complications. , 2010, Heart rhythm.

[5]  E. W. Hancock,et al.  AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the , 2009, Journal of the American College of Cardiology.

[6]  Li Zhang,et al.  Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. , 2005, Heart rhythm.

[7]  P. Schwartz,et al.  Vagal reflexes following an exercise stress test: a simple clinical tool for gene-specific risk stratification in the long QT syndrome. , 2012, Journal of the American College of Cardiology.

[8]  P. Schwartz,et al.  Nadolol Block of Nav1.5 Does Not Explain Its Efficacy in the Long QT Syndrome , 2012, Journal of cardiovascular pharmacology.

[9]  P. Schwartz.  Newborn ECG screening to prevent sudden cardiac death , 2006 .

[10]  R. Hauer,et al.  Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. , 2012, Journal of the American College of Cardiology.

[11]  P. Schwartz,et al.  Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. , 1976, The American journal of cardiology.

[12]  M. Ackerman,et al.  Competitive sports participation in athletes with congenital long QT syndrome. , 2012, JAMA.

[13]  L. Jordaens,et al.  Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?: Data From the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry , 2010, Circulation.

[14]  S. Priori,et al.  Cost-effectiveness of neonatal ECG screening for the long QT syndrome. , 2006, European heart journal.

[15]  A. Moss,et al.  Stress and sudden death. The case of the long QT syndrome. , 1991, Circulation.

[16]  M. Ackerman,et al.  Epinephrine QT Stress Testing in the Evaluation of Congenital Long-QT Syndrome: Diagnostic Accuracy of the Paradoxical QT Response , 2005, Circulation.

[17]  S. Priori,et al.  Association of Long QT Syndrome Loci and Cardiac Events Among Patients Treated With β-Blockers , 2004 .

[18]  A Malliani,et al.  Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. , 1975, American heart journal.

[19]  A. Wilde,et al.  The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. , 2010, Journal of the American College of Cardiology.

[20]  S. Priori,et al.  Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. , 2004, JAMA.

[21]  Lia Crotti,et al.  Long-QT syndrome: from genetics to management. , 2012, Circulation. Arrhythmia and electrophysiology.

[22]  J. Graham,et al.  Genetic Testing for Long-QT Syndrome: Distinguishing Pathogenic Mutations From Benign Variants , 2010 .

[23]  Carlo Napolitano,et al.  Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.

[24]  G. Breithardt,et al.  Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .

[25]  P. Schwartz.  Cutting nerves and saving lives. , 2009, Heart rhythm.

[26]  S. Priori,et al.  Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. , 2000, Circulation.

[27]  A. George,et al.  Molecular mechanism for an inherited cardiac arrhythmia , 1995, Nature.

[28]  P. Schwartz,et al.  All LQT3 patients need an ICD: true or false? , 2009, Heart rhythm.

[29]  S. Priori,et al.  The Elusive Link Between LQT3 and Brugada Syndrome: The Role of Flecainide Challenge , 2000, Circulation.

[30]  M. Ackerman,et al.  β-Blocker Therapy Failures in Symptomatic Probands with Genotyped Long-QT Syndrome , 2004, Pediatric Cardiology.

[31]  P. Schwartz,et al.  Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation? , 2006, Journal of the American College of Cardiology.

[32]  P. Schwartz,et al.  Malignant Perinatal Variant of Long-QT Syndrome Caused by a Profoundly Dysfunctional Cardiac Sodium Channel , 2008, Circulation. Arrhythmia and electrophysiology.

[33]  R. Gow.  Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. , 2001, Circulation.

[34]  Bba,et al.  Clinical Aspects of Type-1 Long-QT Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene , 2007, Circulation.

[35]  S. Priori,et al.  Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. , 2004, Heart rhythm.

[36]  Calum A MacRae,et al.  Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.

[37]  M. Arita,et al.  Comparison of the effects of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K+ current of guinea-pig ventricular myocytes. , 1996, Journal of molecular and cellular cardiology.

[38]  D. Tester,et al.  Diagnostic Miscues in Congenital Long-QT Syndrome , 2007, Circulation.

[39]  B. Kerem,et al.  Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? , 2000, Circulation.

[40]  P. Schwartz,et al.  Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome. , 1994, Journal of the American College of Cardiology.

[41]  M. Ackerman,et al.  Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience. , 2010, Heart rhythm.

[42]  Michael J Ackerman,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[43]  R. Myerburg,et al.  Electrocardiograms Should Be Included in Preparticipation Screening of Athletes , 2007, Circulation.

[44]  P. Schwartz,et al.  Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy. , 2010, Heart rhythm.

[45]  S. Priori,et al.  High Efficacy of β-Blockers in Long-QT Syndrome Type 1: Contribution of Noncompliance and QT-Prolonging Drugs to the Occurrence of β-Blocker Treatment “Failures” , 2009, Circulation.

[46]  Peter J. Schwartz,et al.  Diagnostic Criteria for the Long QT Syndrome An Update , 1993, Circulation.

[47]  D. Tester,et al.  Genetic Testing for Potentially Lethal, Highly Treatable Inherited Cardiomyopathies/Channelopathies in Clinical Practice , 2011, Circulation.

[48]  H. L. Stone,et al.  Effects of Unilateral Stellectomy upon Cardiac Performance during Exercise in Dogs , 1979, Circulation research.

[49]  D. Tester,et al.  Spectrum and Frequency of Cardiac Channel Defects in Swimming-Triggered Arrhythmia Syndromes , 2004, Circulation.

[50]  P. Schwartz,et al.  Idiopathic long QT syndrome: progress and questions. , 1985, American heart journal.

[51]  Michael J Ackerman,et al.  Genetic Testing for Long-QT Syndrome: Distinguishing Pathogenic Mutations From Benign Variants , 2009, Circulation.

[52]  Fabio Mosca,et al.  Prevalence of the Congenital Long-QT Syndrome , 2009, Circulation.

[53]  S. Popov,et al.  [Long Q-T syndrome]. , 1986, Kardiologiia.

[54]  P. Schwartz,et al.  QTc behavior during exercise and genetic testing for the long-QT syndrome. , 2011, Circulation.

[55]  M. Ackerman,et al.  Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. , 2009, Heart rhythm.

[56]  Derick R. Peterson,et al.  Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-go–Related Gene Potassium Channel , 2002, Circulation.

[57]  S. Priori,et al.  Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome , 2004, Circulation.

[58]  A. Wilde,et al.  Exercise extreme caution when calling rare genetic variants novel arrhythmia syndrome susceptibility mutations. , 2010, Heart rhythm.

[59]  A. Moss,et al.  The Common Long-QT Syndrome Mutation KCNQ1/A341V Causes Unusually Severe Clinical Manifestations in Patients With Different Ethnic Backgrounds: Toward a Mutation-Specific Risk Stratification , 2007, Circulation.

[60]  S. Priori,et al.  Long QT Syndrome: Genotype-Phenotype Correlations , 2004 .

[61]  Michael J. Ackerman,et al.  Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. , 2011, Journal of the American College of Cardiology.

[62]  Y. Gedik,et al.  The Jervell and Lange-Nielsen syndrome. , 1994, International journal of cardiology.

[63]  A. Moss,et al.  The long QT syndrome: a prospective international study. , 1985, Circulation.

[64]  H. L. Stone,et al.  Left stellectomy and denervation supersensitivity in conscious dogs. , 1982, The American journal of cardiology.

[65]  Peter J. Schwartz,et al.  Clinical aspects of ventricular repolarization , 1989 .

[66]  D. Tester,et al.  Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. , 2004, Heart rhythm.

[67]  Lauri Toivonen,et al.  The Jervell and Lange-Nielsen Syndrome: Natural History, Molecular Basis, and Clinical Outcome , 2006, Archives des maladies du coeur et des vaisseaux.

[68]  E. W. Hancock,et al.  AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American , 2009, Journal of the American College of Cardiology.

[69]  Barry J Maron,et al.  Recommendations for interpretation of 12-lead electrocardiogram in the athlete. , 2009, European heart journal.

[70]  M. Bitner-Glindzicz,et al.  The Jervell and Lange-Nielsen syndrome. , 2000, Advances in oto-rhino-laryngology.

[71]  S. Priori,et al.  Gating Properties of SCN5A Mutations and the Response to Mexiletine in Long-QT Syndrome Type 3 Patients , 2007, Circulation.

[72]  A. Moss,et al.  Ranolazine Shortens Repolarization in Patients with Sustained Inward Sodium Current Due to Type‐3 Long‐QT Syndrome , 2008, Journal of cardiovascular electrophysiology.